2026-04-29T06:15:50Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/230672024-11-29T14:06:11Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud
author
Alvarez, R
author
Musteanu, M
author
Garcia-Garcia, E
author
Lopez-Casas, P P
author
Megias, D
author
Guerra, Carmen
author
Muñoz, M
author
Quijano, Y
author
Cubillo, A
author
Rodriguez-Pascual, J
author
Plaza, C
author
de Vicente, E
author
Prados, S
author
Tabernero, S
author
Barbacid, Mariano
author
Lopez-Rios, F
author
Hidalgo, M
funder
Unión Europea. Comisión Europea. European Research Council (ERC)
2024-09-16T08:16:53Z
2024-09-16T08:16:53Z
2014-10-14
Br J Cancer . 2014 ;111(8):1677-8
https://hdl.handle.net/20.500.12105/23067
24642623
10.1038/bjc.2014.129
1532-1827
British journal of cancer
eng
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.
letter to the editor
URL
https://repisalud.isciii.es/bitstreams/efa6b971-1b24-4f07-8752-2d1630fd9c58/download
File
MD5
c85d9af67f058e61a66fee8b184cf7bf
167546
application/pdf
replycommentsonstromal_2014.pdf
URL
https://repisalud.isciii.es/bitstreams/ea79bd9d-c073-4b98-8ad3-c3b9cd9f44e6/download
File
MD5
61d8957592966c048bced474dc601cf6
17130
text/plain
replycommentsonstromal_2014.pdf.txt